Activity

Activity ID

14452

Expires

May 30, 2026

Format Type

Enduring

CME Credit

1

Fee

$30

CME Provider: American Medical Association

Description of CME Course

Management guidelines for type 2 diabetes (T2D) recommend a complications-centric approach, whereby glucose-lowering agents are selected based on an individual’s comorbid conditions. Agents in the sodium glucose cotransporter inhibitor and glucagon-like peptide-1 receptor agonist classes have shown risk reduction in atherosclerotic cardiovascular disease, chronic kidney disease, and heart failure, among other comorbidities, in people with T2D. Yet these agents are underutilized, with barriers to use including lack of knowledge on cardiovascular and renal benefits, competing comorbidities, and fear of adverse events. All members of the multidisciplinary care team play critical roles in reducing risk of comorbidities alongside managing blood glucose levels. They should therefore be well educated on prevention, diagnosis, and management of all T2D-related comorbid conditions to provide effective, personalized care.

This activity features 4 cases of individuals with T2D and comorbid conditions, and the learner progresses through each case by answering a series of quick-hit clinical decision questions. Following each decision point, learning reinforcement will be provided through supporting evidence. Each case will conclude with an expert roundtable discussion of clinical implications of various management approaches.

Disclaimers

1. This activity is accredited by the American Medical Association.
2. This activity is free to AMA members.

Register for this Activity

ABMS Member Board Approvals by Type
More Information
Commercial Support?
No

NOTE: If a Member Board has not deemed this activity for MOC approval as an accredited CME activity, this activity may count toward an ABMS Member Board’s general CME requirement. Please refer directly to your Member Board’s MOC Part II Lifelong Learning and Self-Assessment Program Requirements.

Educational Objectives

Learning Objectives 1. Describe the associations between T2D and CKM comorbidities and the need for early and appropriate screening, diagnostic, and risk management approaches 2. Interpret clinical trial data supporting the use of guideline-recommended agents to reduce CKM risk in people with T2D 3. Choose the most appropriate agent(s) with proven CKM benefits for individuals with T2D, using an evidence-based approach that focuses on improving comorbidities 4. Collaborate with the multidisciplinary team to provide individualized care to people with T2D and CKM comorbidities

Keywords

Diabetes and Endocrinology, Diabetes

Competencies

Medical Knowledge

CME Credit Type

AMA PRA Category 1 Credit

DOI

10.1001/ama.2025.0001976

View All Activities by this CME Provider

The information provided on this page is subject to change. Please refer to the CME Provider’s website to confirm the most current information.